| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a933a0dd561e3e50b278738704d5c6e6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-33 |
| filingDate |
2007-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d78ae7b7cf0e919f874078b46e9497c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_511df2833f6ba1aca1878759da7514b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61892f50aa157d132dff744e63ad7d47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d17eda376e66b100503bd2d30707a6a8 |
| publicationDate |
2009-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20090034297-A |
| titleOfInvention |
Antivirals and Vaccines Against Influenza |
| abstract |
The present invention relates to the development of plasmid DNA vaccines and plasmid DNA primer / protein boost strategies for the prevention of influenza. These vaccines are designed to target H5N1, H1, H3 and other subtypes of influenza and to exert cellular immunity as well as neutralizing antibodies. DNA vaccines are hemagglutinin (HA) or nucleoprotein (NP) from influenza modified codon optimized and / or modified proteolytic cleavage sites of HA that affect the normal function of the protein. Expresses. They are constructed with different CMV / R or CMC / R 8 KB expressions. Adenovirus constructs expressing the same inserts are constructed for an initiation amplification strategy. Protein-based vaccines based on protein production from insect or mammalian cells have been developed using a foldon triple stabilzation domain with or without cleavage to facilitate protein purification. . Another embodiment of the invention relates to the application of an HA pseudotyped lentiviral vector for use in screening neutralizing antibodies in patients and in screening diagnostic and therapeutic antiviral agents such as monoclonal antibodies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018056528-A3 |
| priorityDate |
2006-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |